Avandia and the Commercial Impact of FDA's Credibility Gap

GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.

By Ramsey Baghdadi

For GlaxoSmithKline PLC, an FDA advisory committee recommendation that the diabetes drug rosiglitazone (Avandia) stay on the market is cause...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet